[
icmr
]
India's Covid-19 vaccines will be effective against new variants, says ICMR
ANI, Thiruvananthapuram
PUBLISHED ON FEB 19, 2021 10:16 AM IST
Dr Balram Bhargava, Director General of ICMR, said a paper on Covaxin's neutralisation potential against the UK strain has been accepted for publication.
ICMR DG says India controlled spread of Covid-19 faster than other nations
By hindustantimes.com | Edited by Shankhyaneel Sarkar, Hindustan Times, New Delhi
UPDATED ON FEB 03, 2021 05:38 PM IST
- Bhargava also lauded healthcare officials and India’s vaccine manufacturers for quickly developing the two Covid-19 vaccines - Covishield and Covaxin - within a short period of time.
Covaxin recipients to be monitored for three months after second dose
By Rhythma Kaul
UPDATED ON JAN 21, 2021 04:38 AM IST
If a serious adverse event is linked to vaccination, then the recipient will be compensated based on the national drug controller’s recommendations after thorough investigation, said the plan.
25,800 volunteers enroll for Bharat Biotech’s Covid-19 vaccine’s Phase III trials
By Asian News International | Posted by Shankhyaneel Sarkar | Hyderabad
PUBLISHED ON JAN 07, 2021 08:02 PM IST
The indigenous vaccine has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).
Ahead of launch, Centre issues warning against fake ‘Co-WIN’ apps
By hindustantimes.com| Edited by: Harshit Sabarwal | Hindustan Times, New Delhi
UPDATED ON JAN 06, 2021 07:10 PM IST
“Some apps named ‘CoWIN’ apparently created by unscrupulous elements to sound similar to upcoming official platform of Govt, are on App stores. Don’t download or share personal information on these. Dept official platform will be adequately publicised on its launch,” the Union health ministry said, according to news agency ANI.
‘Bharat Biotech vaccine approved in clinical trial mode, consent of participants has to be taken’: ICMR
By hindustantimes.com | Edited by: Amit Chaturvedi | Hindustan Times, New Delhi
UPDATED ON JAN 06, 2021 10:17 AM IST
Industry experts and some opposition leaders have expressed concern over the absence of Phase 3 trial data on Covaxin.
‘2 vaccines a result proactive approach,’ says DG-ICMR
By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON JAN 04, 2021 05:48 AM IST
“These kinds of approvals are purely data-driven, and in both these vaccines Phase 2 immunogenicity has been well established. The question of approving a vaccine without adequate data does not arise as the expert panel minutely scans the national as well international data presented to them before granting an approval,” said DG-ICMR.
Bharat Biotech vaccine more likely to work against newer strains like UK variant: Vardhan
By Press Trust of India | Posted by Kanishka Sarkar | New Delhi
UPDATED ON JAN 04, 2021 12:08 AM IST
India’s drugs regulator on Sunday approved Oxford Covid-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.
DCGI gives licensing permission to Bharat Biotech to manufacture Covaxin
By hindustantimes.com| Edited by Susmita Pakrasi | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 08:58 PM IST
The DCGI gave final approval to two Covid-19 vaccines, paving the way for a huge inoculation program to stem the pandemic in the second worst-hit country.
‘Bharat Biotech vaccine may have some advantages...’: ICMR chief on Covaxin, mutant strain
By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 08:16 PM IST
Covaxin is a whole virion inactivated Covid-19 vaccine while Oxford vaccine works differently — it produces surface spike protein priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
Bharat Biotech’s Covaxin can be used as backup, says AIIMS Director Dr Randeep Guleria
By hindustantimes.com | Edited by Shivani Kumar | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 06:32 PM IST
The DCGI gave approval for the emergency use of two Covid-19 vaccines, one developed by AstraZeneca and Oxford University and the other by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).
Approval for Covaxin a giant leap for novel product development in India: Bharat Biotech
By Press Trust of India | Posted by Kanishka Sarkar | New Delhi
PUBLISHED ON JAN 03, 2021 02:58 PM IST
The phase-III human clinical trials of Covaxin began mid-November. Bharat Biotech aims to recruit 26,000 volunteers across the country for the phase-III trials.
Drug regulator gives final approval for Covid-19 vaccines of SII, Bharat Biotech
By HT Correspondent | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 01:55 PM IST
Covaxin is the indigenous vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
ICMR: UK strain successfully cultured in India
By Anonna Dutt | Hindustan Times, New Delhi
PUBLISHED ON JAN 03, 2021 01:27 AM IST
Culture is the process by which cells are grown under controlled conditions, generally outside their natural environment.
In a first, India successfully isolates, cultures UK-variant of Sars-CoV-2: ICMR
By hindustantimes.com | Edited by Kanishka Sarkar | Hindustan Times, New Delhi
UPDATED ON JAN 02, 2021 07:08 PM IST
India has reported 29 cases of the new coronavirus variant, that is spreading rapidly around Britain and other countries, within five days of tracing its first such infection.
Bihar: 45 UK returnees untraceable, 101 test negative for new Covid strain
By Ruchir Kumar | Hindustan Times, Patna
PUBLISHED ON JAN 01, 2021 09:04 AM IST
The ministry of civil aviation had sent the state a list of 226 passengers who reached Bihar between November 21 and December 21. At least 96 of these passengers are believed to be from Patna
Mutant strains emphasise the need for strict controls
By Narinder K Mehra
UPDATED ON DEC 31, 2020 05:43 AM IST
It is important to keep the viral load in check so that the natural benefits India’s population enjoys of broad-based immunity can be best made use of
Experimental therapies not to be used indiscriminately, warns ICMR
By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON DEC 30, 2020 01:59 AM IST
The warning comes in the backdrop of the discovery in the UK of a new variant of the virus that causes Covid-19. The new strain, scientists say, is more transmissible than the original one.
Non-judicious use of therapies for Covid-19 leads to virus mutations: ICMR chief
By Asian News International | Posted by Srivatsan K C | New Delhi
PUBLISHED ON DEC 29, 2020 09:03 PM IST
“Those therapies which are being touted as ‘anti-viral’ or ‘anti-COVID therapies’ and they have do not have benefits established in a scientific research paper, those therapies should not be used as they will put tremendous immune pressure on the virus and it will tend to mutate more, Dr Bhargava told ANI.
ICMR Assistant admit card 2020 released at pgimer.edu.in, here’s direct link
By hindustantimes.com | Edited by Akhilesh Nagari | Hindustan Times, New Delhi
UPDATED ON DEC 27, 2020 01:52 PM IST
ICMR Assistant admit card 2020: Candidates who have registered for the examination can download the admit card online at icmr.gov.in and pgimer.edu.in.
14 UK returnees test Covid-19 positive in Karnataka, samples sent to NIMHANS for further tests
By Venkatesha Babu | Hindustan Times, Bengaluru
UPDATED ON DEC 26, 2020 10:42 PM IST
Karnataka medical education minister Dr K Sudhakar said that 1,638 out of 2,500 returnees from the UK have been tested and 14 of them have been found positive.
Fewest daily virus cases in Delhi for 131 days; 30 deaths
By HT Correspondent | Hindustan Times, New Delhi, New Delhi
UPDATED ON DEC 26, 2020 02:03 AM IST
Delhi, in the seven days ending on Friday, recorded a daily average of 952 new infections — the first time this number has dropped below 1,000 since May 31, when it saw a seven-day average of 918 cases.
61% of active Covid-19 cases in Delhi’s 5.5k hot spots: Delhi govt data
By Abhishek Dey | Hindustan Times, New Delhi, New Delhi
UPDATED ON DEC 26, 2020 05:18 AM IST
The government attributed the sharp increase in the share of active Covid-19 cases in red zones to its micro-containment policy, which was intensified in November.
Indian vaccine Covaxin has drawn global attention: ICMR
By Asian News International | Posted by Prashasti Singh | New Delhi
UPDATED ON DEC 25, 2020 07:04 AM IST
The All India Institute of Medical Sciences (AIIMS) based in New Delhi on Thursday invited volunteers for the Phase III clinical trial of the indigenously developed Covid-19 vaccine candidate ‘Covaxin’ for which it is one of the sites.
Price cap on Covid tests could be affecting diagnosis, skewing data
By Sanchita Sharma | Hindustan Times, New Delhi
UPDATED ON DEC 24, 2020 05:00 AM IST
The ORF-1a, RdRp, E, N, and S genes are most frequently targeted for Sars-CoV-2 detection by reverse transcription-polymerase chain reaction (RT-PCR) testing, which is the standard test for Covid-19 diagnosis in India. The test that can successfully identify the variant is a three-gene test, where one of the genes doesn’t show up in the result because of a mutation in the virus.
New Covid strain may be in India already: Experts
By Anonna Dutt | Hindustan Times, New Delhi
UPDATED ON DEC 23, 2020 01:11 PM IST
The new variant, VUI–202012/01, which accounted for nearly 60% of all cases in London by mid-December, is thought to be 70% more transmissible than earlier versions of the coronavirus. Scientists are still researching on the effects, virulence and severity of the new strain.
Covid-19: Govt to decide on reserving 80% beds in pvt hospitals today
By Richa Banka | Hindustan Times, New Delhi
UPDATED ON DEC 23, 2020 01:26 AM IST
The government further told the court that due to the current evolving situation of a new Covid-19 strain, the government order of reserving the beds would be reviewed on December 23.
Bharat Biotech’s Covid-19 vaccine phase-3 trials cross half-way mark of 13,000 volunteers
By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON DEC 22, 2020 12:57 PM IST
Covaxin, India’s indigenous Covid-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research-National Institute of Virology
India suspends UK flights
By Anisha Dutta and Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON DEC 22, 2020 06:28 AM IST
All passengers who arrive from the UK on December 21 and 22 will be asked to take an RT-PCR test for Covid-19 at the airport, with only those who test negative be allowed to go home, where they will need to isolate for seven days.
New Covid strain not yet found in India: Experts
By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON DEC 22, 2020 08:56 AM IST
The new strain is feared to be more infective and could 70% more transmissible, experts in UK said over the weekend, prompting over 40 nations – including India – to suspend flight operations.